Clinical Trials

View All Clinical Trials

Search Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

No search term entered. 236 results shown below.

Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma

[Complete title: A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial]
Principal Investigator: David Maloney, MD, PhD
Study Number: 1409.00
Phase: I/II

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

[Complete title: Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected with HIV-1 Using a Non-Marrow Ablative Conditioning Regimen Containing TBI in Combination with Post-Transplant Immunosuppression with Cy]
Principal Investigator: Ann Woolfrey, MD
Study Number: 1410.00
Phase: I

Fludarabine Phosphate and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatin

[Complete title: Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia – a Multi-Center Trial]
Principal Investigator: George Georges, MD
Study Number: 1581.00
Phase: II

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody with Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients with Advanced AML or High Risk Myelodysplastic Syndrome]
Principal Investigator: John Pagel, MD, PhD
Study Number: 1809.00
Phase: II

Fludarabine, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

[Complete title: Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 1840.00
Phase: II

Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas

[Complete title: Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells for Patients with Malignant Gliomas]
Principal Investigator: Hans-Peter Kiem, MD
Study Number: 2000.00
Phase: I/II

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

[Complete title: A Multi-center Phase III Study of Autologous Transplantation for Patients with Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine with Melphalan 200 mg/m2 + Amifostine]
Principal Investigator: Bill Bensinger, MD
Study Number: 2004.00
Phase: III

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

[Complete title: Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-dose TBI and Fludarabine With or Without Campath®]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2007.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant, Cyclophosphamide, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Immunodeficiency or Noncancerous Inherited Disorders

[Complete title: HLA-Haploidentical Related Marrow Grafts for the Treatment of Immunodeficiency and Other Nonmalignant Disorders Using Conditioning with Low-Dose Cyclophosphamide, 200 cGy TBI and Fludarabine; Postgrafting Immunosuppression Will Consist of a Single Low Dos]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2032.00
Phase: II

Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)

[Complete title: Fludarabine-based Conditioning for Allogeneic Marrow Transplantation from HLA-compatible Unrelated Donors in Severe Aplastic Anemia]
Principal Investigator: Joachim Deeg, MD
Study Number: 2051.00
Phase: I/II

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

[Complete title: Low-dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders -- A Multi-Ce]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2056.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

[Complete title: Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia Using Alternative Marrow Donors: A Phase I/II Dose-Finding Study]
Principal Investigator: Hans-Peter Kiem, MD
Study Number: 2064.00
Phase: I/II

Nonmyeloablative transplant for severe systemic sclerosis

[Complete title: Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2067.00
Phase: I/II

Autologous Stem Cell Transplantation Followed by Allogeneic Stem Cell Transplantation and Bortezomib Maintenance Therapy for Patients with Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

[Complete title: Tandem Autologous HCT / Nonmyeloablative Allogeneic HCT from HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients with High-Risk Multiple Myeloma]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2070.00
Phase: II

Gene Therapy for Fanconi Anemia

[Complete title: Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA)]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 2097.00
Phase: I

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

[Complete title: A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD]
Principal Investigator: Marie Bleakley, MD
Study Number: 2222.00
Phase: II

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

[Complete title: A Multicenter Phase I/II Study of the Prophylactic Inhibition of BCR-ABL Tyrosine Kinase by Tasigna ® (Nilotinib) after Hematopoietic Cell Transplantation for Philadelphia Chromosome-Positive Leukemias]
Principal Investigator: Paul Carpenter, MD
Study Number: 2223.00
Phase: I/II

Laboratory-Treated T Cells With or Without Ipilimumab in Treating Patients With Metastatic Melanoma

[Complete title: Phase I/II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and anti-CTLA4 For Patients With Metastatic Melanoma]
Principal Investigator: Aude Chapuis, MD
Study Number: 2225.00
Phase: I/II

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-Cell Lymphoma

[Complete title: Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Relapsed or Refractory CD20+ B-Cell Malignancies]
Principal Investigator: Andrew Rezvani, MD
Study Number: 2226.00
Phase: II

Azacitidine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

[Complete title: Treatment of Post-Transplant Relapse and Persistent Disease in Patients with MDS, CMML and AML with Azacitidine]
Principal Investigator: Bart Scott, MD
Study Number: 2240.00
Phase: II

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

[Complete title: Bortezomib and Vorinostat as Maintenance Therapy after Autologous Stem Cell Transplant for Multiple Myeloma]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2253.00
Phase: II

Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

[Complete title: Allogeneic Hematopoietic Cell Transplantation for Patients with Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2256.00
Phase: II

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: A Multi-Center Study of Conditioning with Treosulfan, Fludarabine and Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia]
Principal Investigator: Boglarka Gyurkocza, MD
Study Number: 2272.00
Phase: II

Vorinostat, Gemtuzumab Ozogamicin, and Azacitidine in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination with Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older with Relapsed/Refractory non-APL Acute Myeloid Leukemia (AML)]
Principal Investigator: Roland Walter, MD
Study Number: 2288.00
Phase: I/II

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma

[Complete title: Bortezomib and Vorinostat as Maintenance Therapy after Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2292.00
Phase: II

Clofarabine and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes That Have Relapsed or Not Responded to Treatment

[Complete title: Study of Oral Clofarabine Plus Low-Dose Cytarabine in Previously Treated AML and High-Risk MDS Patients at Least 60 Years of Age]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2302.00
Phase: I/II

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

[Complete title: Hematopoietic Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2309.00
Phase: I

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

[Complete title: Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2310.00
Phase: II

Montelukast to Treat Bronchiolitis Obliterans

[Complete title: Multi-Institutional Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults]
Principal Investigator: Paul Martin, MD
Study Number: 2317.00
Phase: II

High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors

[Complete title: Bevacizumab Combined with Sequential High-Dose Chemotherapy for Patients with Poor-Prognosis Relapsed Germ Cell Tumors]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2328.00
Phase: II

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-human Leukocyte Antigen (HLA) Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

[Complete title: Clofarabine in Combination with Cytarabine (Ara-C) and G-CSF Priming Followed by Infusion of Ex Vivo Expanded Cord Blood Progenitors for Patients with AML]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2335.00
Phase: I

Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

[Complete title: A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation]
Principal Investigator: Mary Flowers, MD
Study Number: 2343.00
Phase: II

Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

[Complete title: Targeted Therapy of Bronchiolitis Obliterans Syndrome]
Principal Investigator: Paul Martin, MD
Study Number: 2367.00
Phase: II

Chronic Graft-versus-Host Disease Treatment

[Complete title: A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease]
Principal Investigator: Paul Carpenter, MD
Study Number: 2375.00
Phase: II/III

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

[Complete title: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 2398.00
Phase: II

Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: Cyclosporine Modulation of Drug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study]
Principal Investigator: Roland Walter, MD
Study Number: 2409.00
Phase: I/II

Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia

[Complete title: A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR]
Principal Investigator: Vivian Oehler, MD
Study Number: 2412.00
Phase: I

Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: Safety and Clinical Activity of Treanda® (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Age >= 50 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2413.00
Phase: I/II

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

[Complete title: A Phase 1 Study of Nilotinib in Steroid Dependent / Refractory Chronic Graft Versus Host Disease]
Principal Investigator: Paul Carpenter, MD
Study Number: 2423.00
Phase: I

Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML]
Principal Investigator: Boglarka Gyurkocza, MD
Study Number: 2430.00
Phase: II

Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

[Complete title: A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2434.00
Phase: III

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

[Complete title: A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2450.00
Phase: I

AKT Kinase Inhibitor MK-2206 With Relapsed Refractory Acute Myelogenous Leukemia

[Complete title: Phase 2 Study of the AKT Kinase inhibitor MK-2206 in Patients with Relapsed/Refractory Acute Myelogenous Leukemia]
Principal Investigator: Roland Walter, MD
Study Number: 2466.00
Phase: II

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

[Complete title: A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL with Lenalidomide alone or with Rituximab]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2467.00
Phase: II

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (anti-CD45) Antibody followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2468.00
Phase: I

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

[Complete title: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 6]
Principal Investigator: Bill Bensinger, MD
Study Number: 2477.00
Phase: III

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma

[Complete title: AMC PROTOCOL #075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma. A Trial of the AIDS Malignancy Consortium (AMC)]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2483.00
Phase: I/II

Autologous Transplant in HIV Patients (BMT CTN 0803)

[Complete title: High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-Infected Patients. BMT-CTN Protocol 0803 (AMC 071)]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2485.00
Phase: II

Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

[Complete title: A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia]
Principal Investigator: Bart Scott, MD
Study Number: 2497.00
Phase: III

Lenalidomide in Treating Patients With AIDS-Related Kaposi Sarcoma

[Complete title: A Phase I/II Study of Lenalidomide in Patients with AIDS-Associated Kaposi’s Sarcoma]
Principal Investigator: Corey Casper
Study Number: 2507.00
Phase: I/II

High-Dose Cyclophosphamide and Anti-Thymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Systemic Scleroderma

[Complete title: A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2533.00
Phase: II

Cyclophosphamide for Preventing Graft-Versus-Host Disease After Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

[Complete title: A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2541.00
Phase: II

Intermittent Hormone Therapy in Men with Localized Prostate Cancer who Have Biochemical Relapse After External Beam Irradiation or Radical Prostatectomy
Principal Investigator: Tia Higano, MD
Study Number: 30296
Phase: II

SCORE -- Assessment of Mood, Information Processing and Quality of Life in Prostate Cancer Survivors and Patients
Principal Investigator: Monique Cherrier, PhD
Study Number: 30824
Phase: NA

Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer

[Complete title: A Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients with Stage III and IV Squamous Cell Carcinoma of the Head and Neck]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 6106
Phase: II

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

[Complete title: A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination with Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cance]
Principal Investigator: Jennifer Specht, MD
Study Number: 6488
Phase: II

Combination Chemotherapy, Intensity-Modulated Radiation Therapy, and Surgery in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery

[Complete title: A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients with Locally Advanced, Resectable Pancreatic Adenocarcinoma]
Principal Investigator: Andrew Coveler, MD
Study Number: 6511
Phase: II

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

[Complete title: Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases]
Principal Investigator: Lupe Salazar, MD
Study Number: 6578
Phase: II

Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC

[Complete title: A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 6620
Phase: II

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer

[Complete title: Combined Targeted Therapies for Triple Negative Advanced Breast Cancer – A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib]
Principal Investigator: Jennifer Specht, MD
Study Number: 6628
Phase: II

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

[Complete title: Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer]
Principal Investigator: Nora Disis, MD
Study Number: 6658
Phase: I/II

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

[Complete title: A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)]
Principal Investigator: Marc Chamberlain, MD
Study Number: 6803
Phase: II

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

[Complete title: A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy]
Principal Investigator: Hannah Linden, MD
Study Number: 6856
Phase: Pilot

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

[Complete title: A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy or Have Been Treated with Single Agent Targretin]
Principal Investigator: Andrei Shustov, MD
Study Number: 6914
Phase: II

Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer

[Complete title: Molecular correlates of sensitivity and resistance to therapy in prostate cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 6932
Phase: NA

High-Dose Methotrexate and Liposomal Cytarabine in Treating Patients With Central Nervous System (CNS) Metastases From Breast Cancer

[Complete title: Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients with Leptomeningeal Metastases with or without Parenchymal Brain Involvement]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 6954
Phase: II

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

[Complete title: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors]
Principal Investigator: Eve Rodler, MD
Study Number: 7007
Phase: II

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

[Complete title: A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung]
Principal Investigator: Eve Rodler, MD
Study Number: 7008
Phase: II

Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer

[Complete title: Phase 2 Trial of Radiation with Androgen Deprivation (AbiRAD): Abiraterone Acetate, Prednisone and LHRH Agonist Prior to and Concurrent with Radiation Therapy]
Principal Investigator: Robert Montgomery, MD
Study Number: 7048
Phase: II

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

[Complete title: Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Hi]
Principal Investigator: David Byrd, MD
Study Number: 7108
Phase: III

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

[Complete title: Phase 2 Study Of Clofarabine with High Dose Cytarabine and G-CSF Priming in Adult Patients Less than Age 65 with Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 7144
Phase: II

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

[Complete title: Phase I Study of ABT-888 in Combination with Cisplatin and Vinorelbine for Patients with Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer]
Principal Investigator: Eve Rodler, MD
Study Number: 7161
Phase: I

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

[Complete title: Phase II trial of bevacizumab in patients with recurrent or progressive meningiomas]
Principal Investigator: Marc Chamberlain, MD
Study Number: 7329
Phase: II

Vaccine Therapy in Treating Patients With Stage III-IV Ovarian Cancer

[Complete title: A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients with Advanced Ovarian Cancer]
Principal Investigator: Nora Disis, MD
Study Number: 7396
Phase: I

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

[Complete title: Phase I Clinical Trial of VTX-2337, a small molecule Toll-Like Receptor 8 (TLR8) agonist in combination with cetuximab in patients with recurrent or metastatic squamous cell carcinomas of the head and neck (SCCHN)]
Principal Investigator: Laura Chow
Study Number: 7406
Phase: I

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

[Complete title: A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer]
Principal Investigator: Shilpen Patel, MD
Study Number: 7506
Phase: I

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

[Complete title: A Phase I Clinical Trial of Pazopanib in Combination with Escalating Doses of Radioactive 131I in Patients with Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake]
Principal Investigator: Laura Chow
Study Number: 7529
Phase: I

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

[Complete title: Phase II Trial of Abiraterone Acetate Combined with Dutasteride with Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Signaling in Patients with Metastatic Castrate Resistant Prostate Cancer (CRPC)]
Principal Investigator: Robert Montgomery, MD
Study Number: 7621
Phase: II

International Collaborative Treatment Protocol For Infants Under One Year With Acute Lymphoblastic Or Biphenotypic Leukemia
Principal Investigator: Blythe Thomson, MD
Study Number: CHRMC 2006
Phase: III

Efficacy of Carboplatin Administered Concomitantly with Radiation and Isoretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Principal Investigator: James Olson, MD, PhD
Study Number: COG ACNS0332
Phase: III

European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G. 99)
Principal Investigator: Doug Hawkins, MD
Study Number: COG AEWS0331
Phase: III

Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma
Principal Investigator: Julie Park, MD
Study Number: COG ANBL0532
Phase: III

Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARST0531
Phase: III

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0724/ RTOG 0724
Phase: III

Study Looking at Effectiveness of I-131-Tositumomab (Bexxar) Consolidation for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

[Complete title: A Study of 131I-Tositumomab (Bexxar®) Consolidation in Patients with B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission]
Principal Investigator: John Pagel, MD, PhD
Study Number: PSOC 2301
Phase: II

Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic

[Complete title: A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)]
Principal Investigator: John Pagel, MD, PhD
Study Number: PSOC 2401
Phase: I/II

A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging
Principal Investigator: Oliver Press, MD, PhD
Study Number: SWOG 0816
Phase: II

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

[Complete title: Donor Lymphocyte Infusion for the Treatment Of Malignancy After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 1803.00
Phase: I/II

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

[Complete title: Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multicenter Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 1825.00
Phase: I/II

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer

[Complete title: A Multi-Center Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate M]
Principal Investigator: David Maloney, MD, PhD
Study Number: 1898.00
Phase: II

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2010.00
Phase: II

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

[Complete title: A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Umbilical Cord Blood Progenitors With an Unmanipulated Cord Blood Graft in Patients Undergoing Umbilical Cord Blood Transplantation for Hematologic Malignancies]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2044.00
Phase: I

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia or High-Risk Myelodysplastic S

[Complete title: Hematopoietic Bone Marrow Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Co]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2186.00
Phase: II

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Mul]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2206.00
Phase: II

Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Myeloablative Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected with HIV
Principal Investigator: Ann Woolfrey, MD
Study Number: 2212.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

[Complete title: A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2230.00
Phase: II

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin

[Complete title: A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2238.00
Phase: I

Unrelated Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

[Complete title: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2239.00
Phase: II

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

[Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2241.00
Phase: II

Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy

[Complete title: High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases]
Principal Investigator: George Georges, MD
Study Number: 2260.00
Phase: I/II

Treosulfan, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant

[Complete title: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2275.00
Phase: II

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

[Complete title: Phase I Feasibility Study of Clofarabine and Low Dose Total Body Irradiation (TBI) as a Non-myeloablative Preparative Regimen for Stem Cell Transplantation (SCT) for Hematological Malignancies: a Multi-Center Study]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2284.00
Phase: I

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

[Complete title: Longitudinal Study of Immune Mediated Disorders after Allogeneic HCT]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2342.00
Phase: NA

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

[Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source]
Principal Investigator: Paul O'Donnell, MD, PhD
Study Number: 2372.00
Phase: II

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

[Complete title: Infusion of Off–the-Shelf Ex-Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients with Hematologic Malignancies]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2378.00
Phase: II

Exercise and Stress Management Post Autologous and Allogeneic Transplant

[Complete title: A Phase III Randomized, Multicenter Trial Testing Whether Exercise or Stress Management Improves Functional Status and Symptoms of Autologous and Allogeneic Recipients]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2443.00
Phase: III

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancie]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2448.00
Phase: III

CD19-specific Donor T Cells for B Cell Malignancies After Allogeneic Transplant

[Complete title: A Phase I/II Study of Cellular Immunotherapy with Donor Central Memory-Derived Virus-Specific CD8+ T-Cells Engineered to Target CD19 for CD19+ Malignancies after Allogeneic Hematopoietic Stem Cell Transplant]
Principal Investigator: Cameron Turtle, PhD, MBBS
Study Number: 2494.00
Phase: I/II

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

[Complete title: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2531.00
Phase: II

Bendamustine Hydrochloride, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

[Complete title: A Phase II Study of Bendamustine (B), Etoposide (E) Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)]
Principal Investigator: Ajay Gopal, MD
Study Number: 7176
Phase: II

Cognitive Rehabilitation in Cancer Survivors: A Pilot Study
Principal Investigator: Monique Cherrier, PhD
Study Number: 7279
Phase: NA

Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas

[Complete title: A Phase I Trial of Bendamustine/Treanda, Rituximab, Etoposide and Carboplatin for Patients with Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)]
Principal Investigator: Ajay Gopal, MD
Study Number: PSOC 2502
Phase: I

A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
Principal Investigator: George Laramore, MD, PhD
Study Number: 6864
Phase: III

Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas
Principal Investigator: George Laramore, MD, PhD
Study Number: 7060
Phase: II

Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed Glioblastoma
Principal Investigator: George Laramore, MD, PhD
Study Number: 7196
Phase: II

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

[Complete title: Phase III Study of Radiation Therapy With or Without Temozolomide For Symptomatic or Progressive Low-Grade Gliomas CCIRB#7269]
Principal Investigator: George Laramore, MD, PhD
Study Number: 7294
Phase: III

Intensified Methotrexate, Nelarabine (Compound 506U78 IND # 52611) and Augmented BFM Therapy in Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
Principal Investigator: Blythe Thomson, MD
Study Number: COG AALL0434
Phase: III

A Study of Neurocognitive Function in Children Treated for ALL. A Group-wide, Non-therapeutic Companion Study to AALL0232 and AALL0434
Principal Investigator: Doug Hawkins, MD
Study Number: COG AALL06N1
Phase: NA

A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
Principal Investigator: J. Russell Geyer, MD
Study Number: COG ACNS0331
Phase: III

A Phase I study of the Raf kinase and receptor tyrosine kinase inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in children with refractory solid tumors or refractory leukemias
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0413
Phase: I

A Phase I Study of Temozolomide, oral Irinotecan and Vincristine for Children with Refractory Solid Tumors
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0414
Phase: I

Phase III, Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High-Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Principal Investigator: Julie Park, MD
Study Number: COG ANBL0032
Phase: III

A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone
Principal Investigator: Julie Park, MD
Study Number: COG ANBL00P3
Phase: III

Treatment of Adrenocortical Tumors with Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARAR0332
Phase: III

Treatment of High Risk Renal Tumors; A Groupwide Phase II Study.
Principal Investigator: Doug Hawkins, MD
Study Number: COG AREN0321
Phase: II

Treatment for Very Low, Low, and Standard Risk Favorable Histology Wilms Tumor. A Groupwide Phase III Study
Principal Investigator: Doug Hawkins, MD
Study Number: COG AREN0532
Phase: III

Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Principal Investigator: Doug Hawkins, MD
Study Number: COG AREN0533
Phase: III

A Single Arm Trial of Systemic and Subtenon Chemotherapy for Group C/D Intraocular Retinoblastoma
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARET0231
Phase: III

Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARST0332
Phase: III

A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (<=2 cm) Peripheral Non-Small Cell Lung Cancer
Principal Investigator: Fred Appelbaum, MD
Study Number: CTSU C140503
Phase: III

Phase III Randomized Study of R-Chop V. Dose-Adjusted Epoch-R with Molecular Profiling in Untreated De Novo Diffuse Large B Cell Lymphomas
Principal Investigator: Fred Appelbaum, MD
Study Number: CTSU C50303
Phase: III

Phase II Trial Of Response-Adapted Chemotherapy Based On Positron Emission Tomography For Non-Bulky Stage I And II Hodgkin Lymphoma
Principal Investigator: Fred Appelbaum, MD
Study Number: CTSU C50604
Phase: II

A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin With Bevacizumab, or Cetuximab (C225), or With The Combination of Bevacizumab, or Cetuximab For Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Principal Investigator: Fred Appelbaum, MD
Study Number: CTSU C80405
Phase: III

A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone
Principal Investigator: Fred Appelbaum, MD
Study Number: CTSU C90202
Phase: III

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without bevacizumab for Patients With completely Resected Stage IB (> or = 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Fred Appelbaum, MD
Study Number: CTSU E1505
Phase: III

Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Subjects With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane
Principal Investigator: Fred Appelbaum, MD
Study Number: CTSU N0733
Phase: II

A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel (CT-2103) (IND # 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0212
Phase: III

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC#704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Periton
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0213
Phase: II/III

A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0249
Phase: II/III

A Randomized Phase III Trial of Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0258
Phase: III

A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0261
Phase: III

A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC#683864, IND#61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell C
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0268
Phase: II

Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (IND # 68254)
Principal Investigator: Julie Park, MD
Study Number: NANT 2004-04
Phase: I

Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) with Autologous Stem Cell Support for Resistant/Recurrent High-Risk Neuroblastoma (IND #69,112)
Principal Investigator: Julie Park, MD
Study Number: NANT 9902
Phase: I

A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-39
Phase: III

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-43
Phase: III

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-47
Phase: III

Statin Polyp Prevention Trial in Patients with Resected Colon Cancer
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP P-5
Phase: III

A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0500
Phase: III

Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0518
Phase: III

A Phase II Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0535
Phase: II

A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0702
Phase: NA

A Phase II Trial of Azacitidine plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Older patients with Previously Untreated Non-M3 Acute myeloid Leukemia
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0703
Phase: II

A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI- 774(Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected By Serum Proteomics
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0709
Phase: II

Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517, IND-73969) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0711
Phase: I

A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy of Rectal Cancer
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0713
Phase: II

A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed By Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) As Neoadj
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0800
Phase: II

A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0802
Phase: II

Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) (a BMT Study)
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0805
Phase: II

A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0809
Phase: II

Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

[Complete title: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0819
Phase: III

A Phase II Study of Epratuzumab (NSC-716711) in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Ph-Negative Precursor B-cell Acute Lymphoblastic Leukemia (ALL)
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0910
Phase: II

A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute myelogenous Leukemia
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0919
Phase: II

A Randomized Phase II Study of Combined Androgen Deprivation Versus Combined Androgen Deprivation with IMC-A12 for Patients with New Hormone Sensitive Metastatic Prostate Cancer
Principal Investigator: Evan Yu, MD
Study Number: SWOG 0925
Phase: II

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG 0931
Phase: III

An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG C10403
Phase: II

A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant FOLFOX Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG C80702
Phase: III

A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG C90601
Phase: III

A phase III randomized study of adjuvant ipilimumab anti-ctla4 therapy versus high-dose interferon ?-2b for resected high-risk melanoma
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG E1609
Phase: III

Phase III Randomized Trial of the Effect of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG MA.32
Phase: III

A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG S1005
Phase: II

Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II
Principal Investigator: Fred Appelbaum, MD
Study Number: SWOG S1014
Phase: II

Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

[Complete title: A Multicenter, Open-label Single-arm Study of YONDELIS® (trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment]
Principal Investigator: Eve Rodler, MD
Study Number: 20051530
Phase: III

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

[Complete title: Registration Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-Controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who H]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20062200
Phase: III

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

[Complete title: A Phase I Study Evaluating a Second Generation Antisense Oligonucleotide (OGX-427) that Inhibits Heat Shock Protein 27 (Hsp 27)]
Principal Investigator: Evan Yu, MD
Study Number: 20070773
Phase: I

A Phase 1 Study of MLN9708 in Adult Patients With Advanced Nonhematologic Malignancies

[Complete title: An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies]
Principal Investigator: John Thompson, MD
Study Number: 20082188
Phase: I

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

[Complete title: Single-arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 20091274
Phase: II

An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

[Complete title: Treatment with SGN-35 in patients with CD30-positive hematologic malignancies who have previously participated in an SGN-35 study]
Principal Investigator: Ajay Gopal, MD
Study Number: 20091827
Phase: II

Dose Escalation Study of MLN4924 in Adults With Melanoma

[Complete title: A Phase 1, Open-Label Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Melanoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20091841
Phase: I

Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

[Complete title: A Phase 1, Dose Escalation Study of Plerixafor in combination with Cytarabine and Daunorubicin in Patients with De Novo Acute Myeloid Leukemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20091942
Phase: I

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

[Complete title: A Phase 1 Study of ABT-888 in Combination with Carboplatin and Gemcitabine in Subjects with Advanced Solid Tumors]
Principal Investigator: Heidi Gray, MD
Study Number: 20091988
Phase: I

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC (BRISK TA)

[Complete title: A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Emboliztion (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study]
Principal Investigator: Edward Lin, MD
Study Number: 20092129
Phase: III

MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

[Complete title: Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients wit]
Principal Investigator: Barbara Ann Goff, MD
Study Number: 20100202
Phase: I/II

A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer

[Complete title: A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects with Advanced Renal Cell Carcinoma]
Principal Investigator: John Thompson, MD
Study Number: 20100220
Phase: I

Study of MLN8237 in Patients With Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel/Prednisone Regimen

[Complete title: A Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, or No MLN8237 in Patients with Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel/Prednisone Regimen, Preceded by a Phase I Dose-Escalation Study - Part 1 and 2]
Principal Investigator: Tia Higano, MD
Study Number: 20100481
Phase: II

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma (PICASSO III)

[Complete title: A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma. The PICASSO III - Study IPM3001]
Principal Investigator: Eve Rodler, MD
Study Number: 20100687
Phase: III

A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

[Complete title: Phase 2 Study of Pemetrexed in Combination with Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck]
Principal Investigator: Laura Chow
Study Number: 20100688
Phase: II

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic Adenocarcinoma

[Complete title: A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients with Pancreatic Adenocarcinoma]
Principal Investigator: Andrew Coveler, MD
Study Number: 20100718
Phase: I

First in Human Study to Determine the Safety, Tolerability and Preliminary Effectiveness of MDX-1338 (BMS 936564) in Subjects With Acute Myelogenous Leukemia (AML)

[Complete title: A Phase 1, Open-Label, Multicenter Study of MDX-1338/BMS936564 in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20100803
Phase: I

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)

[Complete title: PREVAIL: A Multinational Phase 3 Randomized, Double-blind Placebo Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer who have Failed Androgen Deprivation Therapy]
Principal Investigator: Tia Higano, MD
Study Number: 20101081
Phase: III

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

[Complete title: A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone with the Immunological Adjuvant OPT-821 versus OPT-821 Alone in Metastatic Sarcoma Patients who are Rend]
Principal Investigator: Eve Rodler, MD
Study Number: 20101150
Phase: II

A Study in Second Line Metastatic Colorectal Cancer

[Complete title: A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy Wit]
Principal Investigator: Veena Shankaran
Study Number: 20101327
Phase: III

A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

[Complete title: A Phase 1b Study Of TRU-016 In Combination With Bendamustine In Patients With Rituximab-Refractory Indolent Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 20101336
Phase: I

A Study of Paclitaxel With or Without Ramucirumab in Metastatic Gastric Adenocarcinoma (RAINBOW)

[Complete title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy W]
Principal Investigator: Edward Lin, MD
Study Number: 20101546
Phase: III

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for Anaplastic Large Cell Lymphoma

[Complete title: A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) as Front-Line Therapy in Patients with Systemic Anaplastic Large Cell Lymphoma]
Principal Investigator: Andrei Shustov, MD
Study Number: 20101576
Phase: I

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

[Complete title: Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy]
Principal Investigator: Robin Jones
Study Number: 20101618
Phase: II

Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma (DELTA)

[Complete title: A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents]
Principal Investigator: Ajay Gopal, MD
Study Number: 20101820
Phase: II

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Carcinoma (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

[Complete title: A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI-906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20110053
Phase: II

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

[Complete title: A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) Chondrosarcoma]
Principal Investigator: Robin Jones
Study Number: 20110074
Phase: II

A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

[Complete title: A Phase I, Multicenter, Open-Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients with Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)]
Principal Investigator: Laura Chow
Study Number: 20110186
Phase: I

A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

[Complete title: Phase 2 Study of MEDI-575 in Adult Subjects with Recurrent Glioblastoma Multiforme]
Principal Investigator: Marc Chamberlain, MD
Study Number: 20110231
Phase: II

Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity

[Complete title: An Open-label, non-randomized Phase 1 study of Regorafenib (BAY 73-4506) to evaluate cardiovascular safety, tolerability, pharmacokinetics and anti-tumor activity in patients with Advanced Solid Tumors]
Principal Investigator: Robin Jones
Study Number: 20110500
Phase: I

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced L-sarcoma

[Complete title: A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated with an Anthracycline and Ifosfamide]
Principal Investigator: Robin Jones
Study Number: 20110545
Phase: III

A Phase 1 Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

[Complete title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin’s Lymphoma (NHL)]
Principal Investigator: Ajay Gopal, MD
Study Number: 20110654
Phase: I

ARCHER 1009 : A Phase 3 Study Of PF-00299804, A Pan-HER Inhibitor, Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

[Complete title: A Randomized Double Blind Phase 3 Efficacy and Safety Study of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer Following Progression After, or Intolerance to, at Least One Prior Chemotherapy]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 20110772
Phase: III

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

[Complete title: A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors]
Principal Investigator: Tia Higano, MD
Study Number: 20110790
Phase: II

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological

[Complete title: A Phase 1, Two-arm, Open-label Study of Once Daily, Oral BMN 673 in Patients With Advanced Hematological Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 20110958
Phase: I

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

[Complete title: A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)]
Principal Investigator: Samuel Whiting, MD, PhD
Study Number: 20111239
Phase: I/II

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

[Complete title: An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leukemias]
Principal Investigator: Roland Walter, MD
Study Number: 2344.00
Phase: I/II

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral MLN9708 in Adult Patients With Relapsed and Refractory Multiple Myeloma

[Complete title: An Open Label, Dose Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second Generation Proteasome Inhibitor, in Adult patients with Relapsed and Refractory Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2360.00
Phase: I

A Study of the Safety and Efficacy of CNTO 328 in Combination With Best Supportive Care Compared to Best Supportive Care in Patients With Multicentric Castleman's Disease

[Complete title: A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s Disease]
Principal Investigator: Corey Casper
Study Number: 2366.00
Phase: II

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

[Complete title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 (brentuximab vedotin) and Best Supportive Care (BSC) versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin’s Lymphoma (HL) Following Autologous Stem Cel]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2374.00
Phase: III

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

[Complete title: An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin’s lymphoma]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2388.00
Phase: III

A Phase 1/2 Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

[Complete title: A Phase 1/2 Study Of Arry-520 In Patients With Relapsed Or Refractory Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2402.00
Phase: I/II

Safety and Efficacy Study of TRU-016 Plus Bendamustine Versus Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia

[Complete title: A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2441.00
Phase: I/II

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence (RESUME)

[Complete title: A Phase-3, Multi-Center, Randomized, Doubleblind, Placebo-Controlled, Parallel-Group Study To Compare Efficacy And Safety Of Pomalidomide In Subjects With Myeloproliferative Neoplasm –Associated Myelofibrosis And Red Blood Cell-Transfusiondependence]
Principal Investigator: Joachim Deeg, MD
Study Number: 2465.00
Phase: III

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (Study No. V212-001

[Complete title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)]
Principal Investigator: Steven Pergam, MD
Study Number: 2472.00
Phase: III

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

[Complete title: A Phase I, Open-Label, Dose-Escalation Study to Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).]
Principal Investigator: Bart Scott, MD
Study Number: 2474.00
Phase: I

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

[Complete title: A Single-Arm, Open-Label, Phase 2 Clinical Trial evaluating Disease Response following Treatment with Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients with High-risk, Smoldering Multiple Myelo]
Principal Investigator: Bill Bensinger, MD
Study Number: 2482.00
Phase: II

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT)

[Complete title: A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy]
Principal Investigator: Scott Tykodi, MD
Study Number: 2489.00
Phase: III

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

[Complete title: A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma]
Principal Investigator: Scott Tykodi, MD
Study Number: 2496.00
Phase: III

A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

[Complete title: An open- label, multicenter, phase I trial of the safety and pharmacokinetics of escalating doses of DCDS4501A in patients with relapsed or refractory B-cell non- Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) and DCDS4501A in Combination]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2501.00
Phase: I

A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

[Complete title: An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman’s Disease]
Principal Investigator: Corey Casper
Study Number: 2502.00
Phase: II

A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

[Complete title: A Multi-Center Phase I, Open-Label, Dose-Finding Pilot Study of the Combination of Carflizomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2512.00
Phase: I

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

[Complete title: A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2513.00
Phase: I

A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)

[Complete title: AN OPEN-LABEL, MULTICENTER, PHASE1b TRIAL OF GA101 IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LYMPHOCYTIC LEUKEMIA]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2514.00
Phase: I

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

[Complete title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2521.00
Phase: III

Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

[Complete title: Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy]
Principal Investigator: David Maloney, MD, PhD
Study Number: 2522.00
Phase: III

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

[Complete title: A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)]
Principal Investigator: Paul Martin, MD
Study Number: 2538.00
Phase: I/II

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

[Complete title: A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined with PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Compared to Gemcitabine Combined with Placebo in Patients with Stage IV Previousl]
Principal Investigator: Sunil Hingorani, MD, PhD
Study Number: 2542.00
Phase: I/II

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

[Complete title: A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zometa® (Every 4 weeks vs. Every 12 weeks) in Patients with Documented Bone Metastases from Breast Cancer]
Principal Investigator: Georgiana Ellis, MD
Study Number: 6979
Phase: III

Study of MDX-1105 in Subjects With Selected Advanced or Recurrent Solid Tumors (MDX1105-01)

[Complete title: A Phase 1, Open label, Multicenter, Dose escalation, Multidose Study of BMS 936559 (MDX 1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors (WIRB's Study#: 1107927, Protocol#: 20082100)]
Principal Investigator: Scott Tykodi, MD
Study Number: 7104
Phase: I

A Study Of PF-04449913 In Select Hematologic Malignancies Or With Dasatinib In Chronic Myeloid Leukemia (CML)

[Complete title: A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of PF-04449913, an Oral Hedgehog Inhibitor, Administered as a Single Agent in Select Hematologic Malignancies or in Combination with Dasatinib in Chronic Myeloid Leukemia (CML)]
Principal Investigator: Vivian Oehler, MD
Study Number: 7106
Phase: I

Immunotherapy Study for Surgically Resected Pancreatic Cancer

[Complete title: A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute ® Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 7259
Phase: III

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

[Complete title: Protocol EC-FV-06: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) In Combination Versus PLD In Participants with Platinum-Resistant Ovarian Cancer]
Principal Investigator: Barbara Ann Goff, MD
Study Number: 7334
Phase: III

Vaccine Therapy in Combination With Ampligen® and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer

[Complete title: Phase I-II Study of HER2 Vaccination with poly(I) • poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients]
Principal Investigator: Lupe Salazar, MD
Study Number: 7425
Phase: I/II

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.